Jeffrey Wolf, MD

Articles

Jeffrey Wolf, MD, on Emerging T-Cell Engagers and Their Impact in Multiple Myeloma

January 9th 2021

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

Jeffrey Wolf, MD, on the Lack of MRD Results at ASH and the Future of Myeloma Trials

Jeffrey Wolf, MD

January 5th 2021

Jeffrey Wolf, MD, explained how studies presented at the recent 2020 ASH Annual Meeting & Exposition did not report what percentage of patients achieved minimal residual disease negativity with therapy for multiple myeloma, and that the future of phase 3 trials should focus on this status in patients.

Jeffrey Wolf, MD, on the Future of MRD and More Sensitive Measuring Techniques in Myeloma

Jeffrey Wolf, MD

January 1st 2021

Wolf touched on the future of MRD and the potential development of more sensitive measuring techniques for patients with multiple myeloma.

Jeffrey Wolf, MD, on Implications of Findings from Multiple Myeloma Study Presented at ASH

Jeffrey Wolf, MD

December 27th 2020

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.